SCHEMBL21106982

SCHEMBL21106982

Nc1ccc(Cl)c(Cc2ccc(-c3ccc(F)nc3)s2)c1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC5A2 P31639 10/20 0.58
SLC5A1 P13866 3/20 0.58
CYP11B2 P19099 2/20 0.36
GRIN2B Q13224 2/20 0.33
GRIN1 Q05586 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
CYP11B1 P15538 1/20 0.33
BCL2L1 Q07817 1/20 0.32
CYP2E1 P05181 1/20 0.32
CYP2A6 P11509 1/20 0.32
CYP2B6 P20813 1/20 0.32
MAP4K4 O95819 1/20 0.32
APP P05067 1/20 0.32
INPPL1 O15357 1/20 0.31
ABCB11 O95342 1/20 0.31
ADORA3 P0DMS8 1/20 0.31
SLC6A4 P31645 1/20 0.31
SLC6A3 Q01959 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2170727 0.86 SLC5A2 (0.59) SLC5A2SLC5A1CYP11B2GRIN2BGRIN1
SCHEMBL4115380 0.85 SLC5A2 (0.58) SLC5A2SLC5A1CYP11B2GRIN2BGRIN1
SCHEMBL14406494 0.85 SLC5A2 (0.61) SLC5A2SLC5A1CYP11B2GRIN2BLMNA
SCHEMBL12714466 0.85 SLC5A2 (0.58) SLC5A2SLC5A1CYP11B2GRIN2BGRIN1
SCHEMBL19493642 0.83 SLC5A2 (0.56) SLC5A2SLC5A1CYP11B2GRIN2BGRIN1
SCHEMBL13278033 0.82 SLC5A2 (0.57) SLC5A2SLC5A1CYP11B2LMNAMAPT
SCHEMBL13896555 0.75 SLC5A2 (0.75) SLC5A2SLC5A1ABCB11ADORA3SLC6A4
SCHEMBL3578722 0.75 SLC5A2 (0.75) SLC5A2SLC5A1ABCB11ADORA3SLC6A4
SCHEMBL22783104 0.74 SLC5A2 (1.00) SLC5A2SLC5A1ABCB11ADORA3SLC6A4
SCHEMBL12714472 0.74 SLC5A2 (0.69) SLC5A2SLC5A1ABCB11ADORA3SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10544135-B2 Process for the preparation of compounds useful as inhibitors of SGLT2 JANSSEN PHARMACEUTICA NV (BE) 2020-01-28 US disclosed
US-20190194177-A1 PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT2 JANSSEN PHARAMCEUTICA NV (BE) 2019-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10544135-B2 Process for the preparation of compounds useful as inhibitors of SGLT2 SLC5A2, SLC5A1, SI SLC5A2 1/4885SLC5A1 2/4885CYP11B2 528/4885
US-20190194177-A1 PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT2 SLC5A2, SLC5A1, SI SLC5A2 1/4885SLC5A1 2/4885CYP11B2 528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.